{"id":951175,"date":"2026-04-14T08:22:10","date_gmt":"2026-04-14T12:22:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs\/"},"modified":"2026-04-14T08:22:10","modified_gmt":"2026-04-14T12:22:10","slug":"biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs\/","title":{"rendered":"Biomerica Launches inFoods\u00ae IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs"},"content":{"rendered":"
\n

\n \u2014 Represents Biomerica\u2019s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy\u00a0<\/em>
\n
\n \u2014 Canada Has One of the Highest IBS Prevalence Rates in the World \u2014 an Estimated 18% vs. 11% Globally <\/em>
\n
\n \u2014 Up to Five Million Canadians May Have IBS, Representing a Significant and Underserved Market Opportunity <\/em>\n <\/p>\n

IRVINE, Calif., April 14, 2026 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA) (\u201cBiomerica\u201d or the \u201cCompany\u201d), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced the commercial launch of its inFoods\u00ae platform in Canada through two strategic partnerships: Phoenix Airmid Biomedical<\/strong>, which will serve as the exclusive Canadian distribution partner, and CanAlt Health Labs<\/strong>, which will provide certified laboratory processing services to support inFoods\u00ae IBS testing across the country.<\/p>\n

This launch represents a significant milestone in Biomerica\u2019s international commercialization strategy, establishing the Company\u2019s first commercial presence in the Canadian market and expanding patient access to its clinically validated, non-pharmaceutical approach to managing gastrointestinal symptoms.<\/p>\n

\n \u201cThe Canadian launch of inFoods\u00ae IBS is a step forward in our global expansion strategy. Canada has one of the largest and most underserved IBS patient populations in the world, and we believe the inFoods\u00ae platform \u2014 backed by peer-reviewed clinical data published in Gastroenterology \u2014 is uniquely positioned to address a critical unmet need. Partnering with Phoenix Airmid and Can Alt gives us a robust, scalable commercial infrastructure from day one, and we look forward to bringing this precision medicine solution to Canadian patients and physicians.\u201d<\/em>\n <\/p>\n

\n \u2014 Zack Irani, Chief Executive Officer, Biomerica<\/strong>\n <\/p>\n

\n The Canadian IBS Market Opportunity<\/strong>\n <\/p>\n

Canada represents a substantial and underserved commercial opportunity for the inFoods\u00ae IBS platform. According to the Canadian Digestive Health Foundation (CDHF) and peer-reviewed research, IBS is a widespread and economically significant condition across the country:<\/p>\n\n\n\n\n\n\n\n\n\n
\n Metric<\/strong>\n <\/td>\n\n Data<\/strong>\n <\/td>\n<\/tr>\n
\n Canadian IBS Prevalence Rate<\/strong>\n <\/td>\n~18% (vs. 11% globally)<\/td>\n<\/tr>\n
\n Estimated Canadians Affected by IBS<\/strong>\n <\/td>\nUp to 5 million<\/td>\n<\/tr>\n
\n Canadians Affected at Any Given Time<\/strong>\n <\/td>\nUp to 20%<\/td>\n<\/tr>\n
\n Impact on Daily Life<\/strong>\n <\/td>\n76% report symptoms impact daily life<\/td>\n<\/tr>\n
\n Work \/ School Absenteeism<\/strong>\n <\/td>\n46% report missing work or school due to IBS<\/td>\n<\/tr>\n
\n IBS-M (Mixed) \u2014 Most Common Canadian Subtype<\/strong>\n <\/td>\n44% of Canadian IBS patients<\/td>\n<\/tr>\n
\n Incremental Annual Cost vs. Non-IBS Patients<\/strong>\n <\/td>\n~USD $2,026 per patient per year<\/td>\n<\/tr>\n<\/table>\n

\n
Despite this burden, treatment options largely focus on treating symptoms through pharmaceutical treatments. The inFoods\u00ae IBS platform \u2014 offering a personalized, non-drug, diagnostic-guided approach \u2014 directly addresses the possible cause of IBS and focuses on unmet clinical needs in this market.<\/p>\n

\n Strategic Partnership Structure<\/strong>\n <\/p>\n

Under the terms of the agreements:<\/p>\n